Amyotrophic Lateral Sclerosis (ALS)
Conditions
Keywords
Amyotrophic Lateral Sclerosis, Motor Neurons, Muscular Atrophy
Brief summary
The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).
Interventions
Intramuscular injection, mecobalamin twice a week.
Sponsors
Eisai Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients who have completed Phase II/III study of E0302 (E0302-J081-761, hereafter referred to as Study 761) except for those patients who discontinued the treatment of Study 761. Completed patients are defined as those who completed the treatment period of Study 761, those on 24-hour use of non-invasive positive pressure ventilation (NIPPV), or those who eventually resulted in the use of NIPPV. 2. Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
Exclusion criteria
1. Patients with cognitive impairment. 2. Pregnant women or women who may have a possibility of becoming pregnant. 3. Patients or their partners who are not willing to use reliable contraception. 4. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to Ministry of Health, Labor and Welfare (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3. However, an event due to the primary disease will be precluded). 5. Patients with malignant tumor. 6. Patients who participated in another clinical study after the completion of Study 761. 7. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock). 8. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with Adverse Events as a Measure of safety | Every 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Survival rate | Every 3 months |
| Functional rating scale | Every 3 months |
| Percent-predicted forced vital capacity (%FVC.) | Every 3 months |
Countries
Japan
Outcome results
None listed